|
Featuring keynote address by Nobel Laureate J. Michael Bishop, MD, this 3-day conference will explore cancer as an individualized problem and address the impact of recent advances in cancer biology, genetics, tumor profiling, and medical technology in the personalization of cancer predisposition, diagnosis, prognosis, treatment, and therapy development.
The main goal of the conference is to foster dialogue among basic and clinical scientists working toward the personalization of cancer medicine and to encourage multidisciplinary collaborations. Furthermore, the experiences shared from different areas of individualized oncology will help improve the global concept of the personalized cancer care, and identify commonalities, pitfalls, and steps forward.
It is expected that the discussions originating from this symposium, their dissemination through enduring materials, and the collaborations emerging from this forum will ultimately generate comprehensive and cross-disciplinary approaches for the translation of our current knowledge of the molecular signatures of cancer into personalized therapies within the cancer care setting.
Call for Poster Abstracts
The deadline for abstract submission is Friday, March 12, 2010. For complete abstract instructions, please send an e-mail to: personalmed@nyas.org. Type the words "Abstract Information" in the subject line—there is no need to type a message. Instructions will be forwarded automatically. Select abstracts will be chosen to participate as oral "Hot Topic" presentations in the plenary sessions. Any questions, please call 212.298.8618.
Presented by
Gold
For a complete list of sponsors, please click the Sponsorship tab.
Agenda
|
* Presentation times are subject to change
|
Day 1: Wednesday, May 19, 2010
|
|
7:45 AM
|
Registration and Breakfast
|
|
8:45 AM
|
Welcome Address
|
Keynote Address
|
|
9:00 AM
|
The Cancer Genome and Therapeutics
Nobel Laureate, J. Michael Bishop, MD, The G.W. Research Hooper Foundation, University of California, San Francisco
|
SESSION I: Biology (Processes Leading to Cancer)
|
|
10:00 AM
|
Deconstructing Metastasis
Joan Massagué, PhD, Memorial Sloan-Kettering Cancer Center
|
|
10:30 AM
|
TBD
|
|
11:00 AM
|
Coffee Break
|
|
11:30 AM
|
Napoleone Ferrara, MD, Genentech, Inc
|
|
12:00 PM
|
Wnt, Lgr5 Stem Cells and Colon Cancer
Hans Clevers, MD, PhD, Hubrecht Institute
|
|
12:30 PM
|
2 investigators selected from abstracts
|
|
1:00 PM
|
Lunch and Poster Session
|
SESSION II: Genetics and Epigenetics (Cancer Susceptibility)
|
|
3:00 PM
|
Therapeutic Cancer Vaccine Development
Yusuke Nakamura, MD, PhD, The University of Tokyo
|
|
3:30 PM
|
Susceptibility to the Common Cancers
Ian Tomlinson, PhD, The Wellcome Trust Centre for Human Genetics, University of Oxford
|
|
4:00 PM
|
2 investigators selected from abstracts
|
|
4:30 PM
|
Coffee Break
|
|
5:00 PM
|
Genetics and Epigenetics of Colon Cancer
Manuel Perucho, PhD, Institute of Predictive and Personalized Medicine of Cancer (IMPPC) and the Burnham Institute for Medical Research, La Jolla
|
|
5:30 PM
|
Stephen B. Baylin, MD, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine
|
|
6:00 PM
|
End Day 1
|
Day 2: Thursday, May 20, 2010
|
|
7:30 AM
|
Registration and Breakfast
|
SESSION III: Oncogenomics and Tumor Profiling
|
|
8:30 AM
|
Todd Golub, MD, Broad Institute
|
|
9:00 AM
|
Gene Fusion Discovery in Cancer
Arul Chinnaiyan, MD, PhD, University of Michigan
|
|
9:30 AM
|
Joe W. Gray, PhD, Lawrence Berkeley National Laboratory
|
|
10:00 AM
|
2 investigators selected from abstracts
|
|
10:30 AM
|
Coffee Break
|
|
11:00 AM
|
René Bernards, PhD, The Netherlands Cancer Institute
|
|
11:30 AM
|
Carlo Croce, MD, Ohio State University
|
|
12:00 PM
|
Lynda Chin, MD, Harvard Medical School
|
|
12:30 PM
|
Lunch and Poster Session
|
SESSION IV: Biomarkers for Prognosis/Response: Impact on Clinical Trials
|
|
2:30 PM
|
Stephen H. Friend, MD, PhD, Sage Bionetworks
|
|
3:00 PM
|
Samir Hanash MD, PhD, Fred Hutchinson Cancer Research Center
|
|
3:30 PM
|
Modeling Personalized Cancer Therapy in Tumor-Derived Cell Lines
Jeffrey Settleman, PhD, Massachusetts General Hospital Cancer Center
|
|
4:00 PM
|
2 investigators selected from abstracts
|
|
4:30 PM
|
Coffee Break
|
|
5:00 PM
|
Molelcular Portraits of Breast Tumors
Charles Perou, PhD, University of North Carolina (Chapel Hill)
|
|
5:30 PM
|
Laura van't Veer, PhD, The Netherlands Cancer Institute
|
|
6:00 PM
|
Molecular Profiling of Pre-Clinical and Clinical Models: Informing the Development of Rational Combinations
James Watters, PhD, Merck & Co., Inc.
|
|
6:30 PM
|
Reception
|
Day 3: Friday, May 21, 2010
|
|
7:30 AM
|
Registration and Breakfast
|
SESSION V: Targeted Therapies I
|
|
8:30 AM
|
Synthetic Lethal Approaches to Cancer Therapy
Alan Ashworth PhD, FMedSci, FRS, The Institute of Cancer Research, London
|
|
9:00 AM
|
Gary Gilliland, MD, PhD, Merck & Co., Inc.
|
|
9:30 AM
|
Targeting the PI3K Pathway
Jose Baselga, MD, Vall d'Hebron University Hospital, Barcelona
|
|
10:00 AM
|
2 investigators selected from abstracts
|
|
10:30 AM
|
Coffee Break
|
Technology Workshop
|
|
11:00 AM
|
Introductory Overview
Brian Pollok, PhD, Life Technologies
|
|
11:10 AM
|
Circulating Tumor Cells
Klaus Pantel, MD, PhD, University Medical Center Hamburg-Eppendorf
|
|
11:30 AM
|
Surgery with Molecular Navigation
Quyen T. Nguyen, MD, PhD, UCSD
|
|
11:50 AM
|
Patient Tumor Genomics
TBD
|
|
12:10 PM
|
Next-Generation Sequencing Technologies
John McPherson, PhD, Ontario Institute for Cancer Research
|
|
12:30 PM
|
Lunch + Poster Session
|
|
2:30 PM
|
PANEL DISCUSSION: From a Subtype Based to a Personalized Cancer Medicine, How Personalized Do We Want to Be?
Moderator: Alison Farrell, PhD, Nature Medicine
4-5 Panelists
|
SESSION VI: Targeted Therapies II
|
|
3:30 PM
|
2 investigators selected from abstracts
|
|
4:00 PM
|
William R. Sellers, MD, Novartis Institutes for Biomedical Research (NIBR)
|
|
4:30 PM
|
Is MEK a Valid Target for the Treatment of Pancreatic Cancer?
Judith Sebolt-Leopold, PhD, University of Michigan
|
|
5:00 PM
|
Charles Sawyers, MD, Memorial Sloan-Kettering Cancer Center
|
|
5:30 PM
|
Closing Remarks and Meeting Adjourns
|
Speakers
Organizers
José Baselga, MD
Vall d'Hebron University Hospital, Barcelona
Alison Farrell, PhD
Nature Medicine
Stephen H. Friend, MD, PhD
Sage Bionetworks
Joan Massagué, PhD
Memorial Sloan-Kettering Cancer Center (Member) and Institute for Research in Biomedicine, Barcelona (Adjunct)
Manuel Perucho, PhD
Institute of Predictive and Personalized Medicine of Cancer, Barcelona and the Burnham Institute for Medical Research
Brian Pollok, PhD
Life Technologies
Keynote Speaker
The G.W. Hooper Research Foundation
University of California, San Francisco
Speakers
Breakthrough Breast Cancer Research Center
Vall d'Hebron University Hospital
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
The Netherlands Cancer Institute
Harvard Medical School
University of Michigan
Hubrecht Institute
Ohio State University
Nature Medicine
Genentech, Inc.
Sage Bionetworks
Merck & Co., Inc.
Broad Institute
Lawrence Berkeley National Laboratory
Fred Hutchinson Cancer Research Center
Memorial Sloan-Kettering Cancer Center
Ontario Institute for Cancer Research
The University of Tokyo
University of California, San Diego
University Medical Center Hamburg-Eppendorf
University of North Carolina, Chapel Hill
The Burnham Institute for Medical Research
Life Technologies
Memorial Sloan-Kettering Cancer Center
University of Michigan
Novartis Institute of Biomedical Research (NIBR)
Massachusetts General Hospital Cancer Center
The Wellcome Trust Centre for Human Genetics, University of Oxford
The Netherlands Cancer institute
Merck & Co., Inc.
Travel & Lodging
Location
Isaac Newton, 26
Barcelona, Spain
Tel. 93 212 60 50 • Fax: 93 253 74 73
Suggested Hotel Accommodations
For special needs please contact: 212.298.8618
|
|